PGR and neoplasm: The striking improvement in terms of pathological complete response (pCR) obtained in endocrine-unresponsive tumours with new schedules of anthracyclines and taxanes has had a lesser impact in ER- and PgR-positive tumours, which obtained pCR up to 10% (Mazouni et al, 2007).